indication

Parkinson's Disease Psychosis

Competitive landscape

as of 2026-07-01
Competitive set
2
2 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
14 events
2018
2020
2022
2024
2026
2028
2030
2032
2034
2036
2038
2040
today
focal launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugRecruiting
Pimavanserin
US-approved 2016 · NUPLAZID
Phase 42 trials
OwnerACADIA Pharmaceuticals Inc.
Protection2039
drugRecruiting
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—

Market size

prevalence as a range, not a number